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Abstract 
Context: Melatonin may play a role in the regulation of the human menstrual cycle and 
may decline with menopause and/or aging.
Objective: The objective of this work is to investigate the relations between melatonin 
and the menstrual cycle, menopause, and aging.
Methods: This was a cross-sectional and longitudinal analysis of 20 participants from 
the Study of Women’s Health Across the Nation (SWAN) Daily Hormone Study (DHS). 
The outcome measure was first-morning urine assay of 6-sulfatoxymelatonin (aMT6s), 
a gauge of melatonin. For each participant, aMT6s was measured daily during one pre-
menopausal cycle with evidence of luteal activity (ELA) and one postmenopausal collec-
tion with no evidence of luteal activity (NELA).
Results: In addition to the organized patterns of hormone metabolites (estrone conju-
gates [E1c], and pregnanediol glucuronide [PdG]) and gonadotropins that characterized 
ovulatory menstrual cycles, there was a late luteal rise in aMT6s. In NELA collections, 
there was no periodicity of E1c, PdG, gonadotropins, or aMT6s. The strongest predictors 
of aMT6s levels were PdG values 11 to 12 days prior to aMT6s (β = 1.46, P =  .001 and 
β = 1.44, P = .001, respectively). E1c and gonadotropins were not statistically significantly 
associated with aMT6s. Mean aMT6s in premenopause was 53.5 ng/mL, greater than the 
mean of 37.4 ng/mL in postmenopausal samples from the same women (P = .0002).
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-
NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction 
and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that 
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Conclusions: This study confirms a late luteal melatonin rise, likely signaled by pro-
gesterone, which may influence menstrual cycle pacemaker control. Melatonin de-
clined from premenopause to postmenopause. A high correlation between menopause 
transition stage and age precludes distinction between the influences of ovarian and 
chronological aging.
Key Words: melatonin, menstrual cycle, menopause, aging
Melatonin, a hormone released from the pineal gland in 
response to darkness, is the biochemical signal of sleep; it 
governs the daily periodicity of the endogenous circadian 
system [1]. However, the physiological influence of mela-
tonin may extend beyond that of circadian pacemaker, 
ranging from control of reproductive function to bone 
balance [2-4].
A pioneering study of melatonin patterns during the 
human menstrual cycle uncovered an organized melatonin 
rise in the late luteal phase [5]. Sampling serum once every 
3 days for a full menstrual cycle in 5 women, Wetterberg 
et al reported that melatonin levels were 4.5 times higher 
in the luteal phase than in the follicular phase and that the 
melatonin rise followed the postovulatory progesterone 
elevation. In another study of 10 women, Webley and 
Leidenberger assayed serum melatonin at 4-hourly inter-
vals on 1 day during the follicular phase and 1 day during 
the luteal phase and reported that melatonin levels were 
significantly higher during the latter [6]. To our knowledge, 
melatonin levels in the normal menstrual cycle have not 
been examined since this early work.
Melatonin may also play a role in the development 
of conditions related to aging and/or menopause. Cross-
sectional reports find that melatonin secretion declines with 
age, raising the possibility that this decrease may, in part, 
underlie the increase in age-related disorders such as poor 
sleep [7, 8]. A  qualitative summary of 20 cross-sectional 
studies estimated that the nocturnal melatonin secretion in 
older adults (age ~ 60-90 years) is about half that of younger 
individuals (age ~ 20-30 years). This large, cross-sectional 
effect size encourages more definitive, longitudinal studies 
of melatonin in relation to aging. The question of whether 
menopause, apart from aging, also influences melatonin se-
cretion is inspired by the concordance between menopause 
transition (MT) symptoms and systems related to mela-
tonin. Examples of the potential menopause symptom-
melatonin intersections include sleep disorders, dysphoric 
mood, and bone loss [9-14].
Our exploratory study, therefore, investigated the rela-
tions between melatonin and the menstrual cycle, meno-
pause, and chronological aging using data and specimens 
from the Study of Women’s Health Across the Nation 
(SWAN) Daily Hormone Study (DHS). SWAN DHS 
participants, who were initially premenopausal, collected 
first-morning urine samples daily for one menstrual cycle 
or, if no bleeding occurred, for 50 days. The SWAN DHS 
assayed metabolites of estrone (estrone conjugates [E1c]), 
progesterone (pregnanediol glucuronide ([PdG]), and 
gonadotropins and applied standard criteria to classify 
each collection as having evidence of luteal activity (ELA) 
or no evidence of luteal activity (NELA) [15, 16]. This 
project newly measured 6-sulfatoxymelatonin (aMT6s), a 
well-established gauge of melatonin, in stored DHS sam-
ples [17]. We analyzed daily aMT6s in one premenopausal 
ELA cycle and one postmenopausal NELA cycle from 20 
DHS participants.
Study aims were to 1) describe within-collection excre-
tion patterns of aMT6s, E1c, PdG, follicle-stimulating hor-
mone (FSH), and luteinizing hormone (LH), stratified by 
ELA or NELA classification; 2)  describe and quantify, if 
present, relations between menstrual cycle excretion pat-
terns of aMT6s and PdG, E1c, and gonadotropins; and 
3)  assess longitudinal, within-woman whole-collection 
excretion of aMT6s in premenopausal ELA compared to 
postmenopausal NELA collections. We proposed 4 hypoth-
eses: 1) in ELA collections, temporal patterns of aMT6s and 
PdG would be related; 2) in NELA collections, which mani-
fest no organized patterns of PdG, E1c, and gonadotropin 
excretion, aMT6s excretion would also be disorganized; 
3) in ELA cycles, the quantity of aMT6s would be directly 
related to the amount of PdG; and 4)  whole-collection 
amount of aMT6 would be less in postmenopausal NELA 
than in premenopausal ELA collections.
1. Materials and Methods
A. Participants
SWAN is the parent study from which the DHS sample was 
derived [18]. In brief, during 1995 to 1997, a community-based 
sample of 16 065 women residing near the 7 SWAN clinical sites 
was screened to yield an inception cohort of 3302 women. All 
sites enrolled White women and each site enrolled one minority 
population (Black, Chinese, Hispanic, or Japanese). Women 
were eligible for the longitudinal SWAN study if they were age 
42 to 52 years, had an intact uterus and at least one ovary, were 
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had 1 or more menstrual periods in the last 3 months, were 
not pregnant/lactating, and self-identified with one of the des-
ignated races/ethnicities. Standardized, uniform questionnaires 
and interviews ascertained participant characteristics. SWAN 
defined premenopause as having menstrual cycles that were 
unchanged from the participant’s usual pattern and early peri-
menopause as having cycles that were less predictable, but with 
no overt gaps of 3 or more months. Experiencing a cycle gap of 
3 or more months defined late perimenopause and 12 months 
of amenorrhea were the criteria for natural menopause.
The SWAN DHS totaled 848 participants [19]. Eligibility 
criteria were the same as those for SWAN. At each SWAN 
visit, DHS volunteers collected a first-morning urine 
sample, starting on their first day of menstrual bleeding 
through the first day of bleeding in the next cycle, or, if no 
menses occurred, for a maximum of 50 days. Collections 
continued for 2 years after their last menstrual period [16]. 
The urinary hormone metabolites and gonadotropin results 
used by the current project were assayed during the DHS. 
The DHS categorized urinary collections as having ELA or 
NELA based on validated criteria [15, 16].
We identified 20 SWAN DHS participants who did 
not report nocturia more than once per week (because we 
sought to estimate overnight aMT6) and who submitted at 
least one ELA cycle prior to menopause (either premeno-
pausal or early postmenopausal cycles qualified) and one 
NELA cycle after menopause. More than 20 women met 
these criteria. Therefore, using the already available DHS 
data, we identified collections that best met ELA and NELA 
criteria (to get the strongest hormone and gonadotropin 
signals with which to compare the aMT6 patterns). We also 
prioritized the ELA-NELA within-woman cycle pairs that 
were farthest apart in calendar time.
B. Laboratory Methods
Existing DHS data included measures of LH, FSH, E1c, 
and PdG, each run by a single, central laboratory on daily 
morning urine samples, using adapted chemiluminescent as-
says, and normalized to creatinine [20]. FSH and LH were 
measured with 2-site chemiluminescent immunoassays 
(Bayer Diagnostics). The range for the urine FSH assay is 0.3 
to 136 mIU/mL, the minimum detectable concentration is 
0.3 mIU/mL, and the interassay and intra-assay coefficients 
of variations (CVs) of the assay are 11.4. The range for the 
LH assay is 0.1 to 55.2 mIU/mL, minimum detectable con-
centration is 0.1 mIU/mL, and interassay and intra-assay CVs 
are 10.9% and 4.6%, respectively. Measures of E1c and PdG 
were performed with competitive immunoassays, adapted to 
chemiluminometric technology (Lasley Center for Health 
and the Environment, 441-437 CHE Labs). The reporting 
range for the E1c assay is 5.10 to 408.0 ng/mL, minimum 
detectable concentration is 0.1  ng/mL, and interassay and 
intra-assay CVs for the E1c assay are 11.5% and 8.1%, re-
spectively. The reporting range for the urine PdG assay is 
0.005 to 25.5  μg/mL, the minimum detectable concentra-
tion is 0.0001 μg/mL, and the interassay and intra-assay CVs 
are 17.8% and 7.7%, respectively. The present study per-
formed aMT6S assays using urine samples from the selected 
DHS collections (which were stored at –80°C) measured by 
enzyme-linked immunosorbent assay (IBL International) 
[21]. Cross-reactivity with other substances tested is less 
than 0.0001% (%  cross-reactivity: melatonin sulfate 100; 
melatonin 0.002; 6-OH-melatonin 0.001; N-acetyl-L-
OH-tryptamine 0.0005; N-acetyl-L-tryptophan  <  0.0001; 
5-methoxy-tryptamine  <  0.0001; tryptamine  <  0.0001; 
5-HIAA < 0.0001). The limit of detection is 1.0 ng/mL, range 
is 5.8 to 204 ng/mL, and CV is 5.2% to 12.2%. Interassay 
measurements are 12.4 to 220 ng/mL with CV of 5.1% to 
14.9%. aMT6s values were normalized to urinary creatinine 
measured in the same urine sample (Sigma-Aldrich Corp; 
creatinine assay results available from the DHS).
C. Data Analysis
To examine day-to-day variation, we plotted the daily mean 
of each analyte (aMT6s, E1c, PdG, FSH, and LH) by men-
strual cycle day over all ELA collections, and by collection 
day over all NELA cycles. Menstrual cycle day 0 designates 
the day of luteal transition (DLT), days prior to the DLT (fol-
licular phase) are designated with negative values, and days 
after the DLT (luteal phase) are given positive values [19].
To quantify relations of aMT6s with PdG, E1c, and 
gonadotropins, we took a 3-step approach. In step 1, we 
inspected the daily mean analyte plots in ELA cycles, to 
identify the peak day of each analyte’s excretion. In step 2, 
we separately regressed the aMT6s value (outcome) against 
lagged values of each of the sex-steroid hormones and 
gonadotropins (predictor) in ELA collections, with lag times 
set at the number of days between the peak days estimated 
(in step 1) of predictor and aMT6s (± 1 day to allow for 
errors in estimation). For example, peak FSH excretion oc-
curred on cycle day 0 and peak aMT6s on cycle day 15, thus 
the lag time between FSH and aMt6s was set at 15 ± 1 days 
(Fig. 1A and 1D. We used individual fixed-effects models 
for the regressions, thereby eliminating between-woman 
differences in all characteristics and isolating relationships 
between within-woman changes in predictor and outcome 
[22]. If we found no evidence of an association between 
aMT6 and predictor in the step 2 regressions (P > .05), we 
ceased analysis for that exposure. In step 3, we regressed 
aMT6 on the candidate exposures and lag times identified 
in step 2 in the combined ELA and NELA data. Again, we 
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NELA collections from the same woman as data from dis-
tinct individuals, to allow for variability in the ELA-NELA 
difference in average hormone levels. If we did find an as-
sociation, we expanded the duration of the lag in both dir-
ections until the association between aMT6 and candidate 
predictor was no longer statistically significant.
To allow for the possibility that aMT6 drives the other 
hormones, we repeated the 3-step analysis with aMT6 as 
predictor and using as dependent variables the sex-steroid 
hormones and gonadotropins that were confirmed to have 
a relationship with aMT6 in the third step of the main 
analysis. Because the aMT6 peak in ELA cycles occurs in 
the luteal phase, the number of days to lag aMT6 for these 
analyses was determined by assuming the ELA cycle re-
peats itself and counting the number of days between the 
aMT6 peak and the hormone/gonadotropin peak in the 
next cycle.
To compare the level of excretion of aMT6s in premeno-
pausal ELA vs postmenopausal NELA collections, we cal-
culated the geometric means of aMT6 over each collection 
after interpolating values for single missing days [20].To stat-
istically test for a difference between ELA and NELA means 
within women, we used linear mixed-effects regression of the 
log-transformed geometric means on ELA/NELA status, with 
a random intercept at the participant level [19, 23].
2. Results
A. Participant Characteristics
The study sample (N  =  20) consisted of 5 Black (25%), 
11 Japanese (55%), and 4 White (20%) women (Table 1). 
Mean age at the first urine collection was 46 years. At the 
second collection, women were an average of 6 years older. 
By design, all were premenopausal at the first collection 
Figure 1. Study participants collected a first-morning urine sample, starting on their first day of menstrual bleeding through the first day of bleeding 
in the next cycle, or, if no menses occurred, for a maximum of 50 days. Fig. 1 graphs daily mean urinary levels of follicle-stimulating hormone (FSH), 
estrone conjugates (E1C), pregnanediol glucuronide (PdG), and 6-sulfatoxymelatonin (aMT6s) over all urine collections that had evidence of luteal 
activity (ELA) [15, 16]. These cycles come from the 20 participants in the current study sample when they were premenopausal. Mean values of each 
analyte are plotted by menstrual cycle day, where day 0 designates the day of luteal transition (DLT), days prior to the DLT (the follicular phase) are 
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and postmenopausal at the second. Table 1 also summar-
izes participants’ anthropometric characteristics at the time 
of each collection.
B. Evidence of Luteal Activity and No 
Evidence of Luteal Activity Patterns of Sex-
Steroid Metabolites, Gonadotropins, and 
6-Sulfatoxymelatonins
Plots of daily mean values of sex-steroid metabolites and 
gonadotropins in ELA cycles according to menstrual cycle 
day (where 0 marks the DLT, negative values indicate days 
prior to DLT, and positive values designate days after the 
DLT) show the expected contours of a cycle that is likely 
ovulatory (Fig.  1A-1C). Unequivocal midcycle surges of 
E1c, FSH, and LH, followed by a luteal phase rise in PdG 
characterized all ELA cycles. The graphs also suggest that 
average daily aMT6s rises in the luteal phase (Fig. 1D). In 
NELA collections, the periodicity of sex-steroid hormones 
and gonadotropins is absent (Fig. 2A-2C). Similarly, aMT6s 
excretion also appears to be unsystematic (Fig. 2D).
C. Follicle-Stimulating Hormone, Luteinizing 
Hormone, Estrone Conjugates, and Pregnanediol 
Glucuronide as Predictors of 6-Sulfatoxymelatonin 
in Evidence of Luteal Activity Cycles
To test the hypothesis that the excretion of aMT6s was 
driven by FSH, LH, E1c, and/or PdG, with a lag of several 
days, we first identified peak cycle days (maximum values) 
of each of these analytes, in ELA cycle patterns (see Fig. 1). 
Proposed peak days by visual inspection were cycle day 
15 for aMT6s, cycle day 0 for FSH and LH, cycle day –1 
for E1c, and cycle day 8 for PdG. We postulated lag times 
between each potential predictor (FSH, LH, E1c, or PdG) 
and aMT6s (outcome) corresponding to the differences be-
tween the predictor peaks and outcome peak, plus or minus 
1 day. Thus, initially tested lag times were 15 ± 1 days for 
the gonadotropins, 16 ± 1 days for E1c, and 7 ± 1 days for 
PdG. This first round of models did not disclose an associ-
ation between LH or E1c levels and aMT6s (Table 2). FSH 
measured 14, 15, or 16 days prior to aMT6s was negatively 
associated with aMT6s (β coefficients = –0.164 to –0.149; 
P = .030-.061). In addition, aMT6s was positively related 
to PdG values from 6, 7, or 8 days prior to aMT6s meas-
urement (β coefficients = 0.115-0.142, ; P = .011-.015).
D. Relations Between 6-Sulfatoxymelatonin, 
Follicle-Stimulating Hormone, and Pregnanediol 
Glucuronide in Evidence of Luteal Activity and 
No Evidence of Luteal Activity Cycles Combined
Building on the lag time hypotheses generated from the ELA 
cycles, we conducted further analysis of the relations between 
the statistically significant predictors of aMT6s, which were 
FSH (lagged by 14-16 days) and PdG (lagged by 6-8 days) (see 
Table 2). The next set of models examined a wider span of lag 
times to discern the lag at which the association between can-
didate predictor and aMT6s was no longer statistically signifi-
cant and included data from both the ELA and NELA cycles. 
PdG was strongly associated with aMT6s at lags ranging from 
6 to 13 days prior to aMT6s level (Table 3). The magnitude 
of the association between PdG and aMT6s became larger as 
the number of lag days increased, reaching maximal effect size 
at 11 to 12 days. PdG values that lagged by 11 days (β co-
efficient = 1.46, P  =  .001) or 12  days (β  coefficient = 1.44, 
P = .001) were the strongest predictors of aMT6s. On day 11, 
the peak day of the association, for each 1-µg/mL rise in PdG, 
aMT6s level goes up by 0.46 ng/m. The magnitude of the as-
sociation between PdG and aMT6s diminished when lagged 
by 13 days and was no longer statistically significant when a 
14-day span was tested. The amount of within-cycle variance 
in aMT6s accounted for by PdG in each of the regressions was 
high: Each R2 was greater than 0.52. In regressions using data 
from both ELA and NELA cycles combined, FSH and aMT6s 
levels were no longer related (see Table 3).
E. Examining 6-Sulfatoxymelatonin as a Predictor 
of Pregnanediol Glucuronide
In ELA and NELA collections combined, PdG was the 
sole significant predictor of aMT6s—however, the bio-
logical relation could be in the reverse direction. We 
Table 1. Characteristics of the Study of Women’s Health 
Across the Nation Daily Hormone Study (SWAN DHS) 




with evidence of 
luteal activity (ELA)b
Postmenopausal 
cycle with no 
evidence of luteal 
activity (NELA)b
Race/Ethnicity
 White 4 (20.0%)
 Black 5 (25.0%)
 Japanese 11 (55.0%)
Age, y 46.00 ± 1.56 52.25 ± 1.80
Body mass index, kg/m2 25.91 ± 4.73 27.20 ± 5.09
Weight, kg 64.56 ± 12.80 67.70 ± 14.29
aSWAN DHS participants who did not report nocturia more than once per 
week, submitted at least one ELA cycle during premenopause, and one NELA 
cycle during postmenopause.
bDHS categorized urinary collections as having ELA with an algorithm that 
uses the degree of rise in progesterone glucuronide excretion as an indicator 
of likely ovulation. Collections that did not meet the ELA standard were clas-
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therefore modeled aMT6s as the predictor of PdG. As 
the first estimate of the lag between predictor and out-
come, we used the number of days between the aMT6 
peak and the PdG peak in the next cycle, assuming the 
cycle repeats. (The lag was based on a visual inspection 
of the hormone graphs, then expanded around the first 
estimate, as described in “Materials and Methods.”) We 
examined the R2 values of each model to gauge which 
direction of prediction had the stronger association (ie, 
PdG predicting aMT6 vs aMT6 predicting PdG). Shown 
in Table 3, the R2 values for models of PdG predicting 
aMT6s, with number of days prior to aMT6 ranging 
from 11 to 16, are between 0.52 and 0.53. We expanded 
the lag times to include PdG 6 days prior to 13 days prior 
to aMT6s; this range was selected based on the β coef-
ficient for PdG remaining statistically significant in each 
model. R2 values for these additional lag times were also 
between 0.52 and 0.53. For the reverse direction, aMT6s 
predicting PdG, we examined lag times of 21 days before 
through 14  days before PdG. (This range was chosen 
based on the β  coefficient for aMT6s remaining statis-
tically significant in each model.) The R2 values of the 
aMT6 predicting PdG models were between 0.33 and 
0.34 (data not shown).
F. Longitudinal Change in 6-Sulfatoxymelatonin
The geometric mean aMT6s value in premenopausal ELA 
samples was 53.5 ng/mL (95% CI, 41.19-69.56 ng/mL), 
statistically significantly greater than the mean of 37.4 ng/
mL (95% CI, 28.80-48.65  ng/mL) in postmenopausal 
NELA samples from the same women; (P  =  .0002 for 
ELA-NELA difference) (data not tabulated). Mean age 
during ELA collections was 46.0  years (range, 43.2-
49.7  years), whereas in NELA visits it was 52.2  years 
(range, 49.2-56.1 years).
Figure 2. Study participants collected a first-morning urine sample, starting on their first day of menstrual bleeding through the first day of bleeding 
in the next cycle, or, if no menses occurred, for a maximum of 50 days. Fig. 2 graphs daily mean urinary levels of follicle-stimulating hormone (FSH), 
estrone conjugates (E1C), pregnanediol glucuronide (PdG), and 6-sulfatoxymelatonin (aMT6s) over all urine collections without evidence of luteal 
activity (NELA) [15, 16]. These cycles come from the 20 participants in the current study sample when they were postmenopausal. Mean values of 
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3. Discussion
Using existing data and new urine aMT6s assays from the 
SWAN DHS, this study identified a cyclic rise in aMT6s, a 
melatonin metabolite, that occurred in the late luteal phase 
of the menstrual cycle. Moreover, the luteal rise in PdG, 
a metabolite of progesterone, predicted the aMT6s rise. 
A  within-woman, longitudinal analysis of aMT6s excre-
tion patterns, first during premenopausal cycles and then 
during postmenopausal collections, generated 2 findings. 
There was no organized pattern of aMT6s excretion in 
postmenopausal cycles, each of which had no evidence of 
luteal activity, and the total amount of aMT6s excretion 
declined by 30% in the postmenopausal collections com-
pared to the premenopausal ones.
Prior studies of melatonin patterns during the human 
menstrual cycle are sparse but concordant with our results. 
In a study of 10 women, Webley and Leidenberger assayed 
serum melatonin at 4-hourly intervals for 1  day during 
the follicular phase and 1 day during the luteal phase and 
reported that melatonin levels were significantly higher 
during the luteal phase [6]. Measuring morning serum 
melatonin and progesterone levels every 3  days for one 
menstrual cycle in a sample of 5 women, Wetterberg and 
colleagues described that a melatonin rise occurred spe-
cifically in the late luteal phase, and that it followed the 
midluteal increase in PdG [5, 24]. The present study adds 
a larger sample size, a daily, overnight urinary estimate of 
aMT6s, and concomitant measures of gonadotropins and 
metabolites of estrogen and progesterone, permitting the 
analysis of daily aMT6s excretion relative to the daily 
hormonal contours of a full menstrual cycle. The longi-
tudinal component, which measured these same analytes 
in a subsequent, postmenopausal, nonovulatory cycle, can 
be viewed as a negative control—the aMT6s rise is absent 
as are the organized patterns of gonadotropins and sex-
steroid hormones.
What is the function of the melatonin rise in the lu-
teal phase of the menstrual cycle? One thesis is that 
melatonin, either directly or indirectly through its anti-
oxidant properties, stimulates progesterone production 
and stabilizes the corpus luteum (CL) [25]. While our 
Table 2. Associations between urinary gonadotropins or 
sex-steroid hormone conjugates and urinary melatonin 
sulfate (aMT6) levels across a range of lag times for each 
candidate predictor in cycles with evidence of luteal activity 
only
Candidate predictors:  
urinary gonadotropins 
and sex-steroid  
hormone conjugates
Lag between  
each candidate 











hormone (FSH),  
mIU/mL
14 –0.164 .03
 15 –0.146 .06




 15 0.117 .68
 16 0.040 .89
Estrone conjugates, ng/ 
mL
15 0.088 .13
 16 0.092 .12




 7 1.142 .01
 8 1.125 .01
aThe lag time between each proposed predictor and aMT6 outcome was based 
on the peak day of each analyte’s excretion relative to the peak day of aMT6s, 
± 1 day. For example, peak FSH excretion occurred on cycle day 0 and peak 
aMT6 on cycle day 15, for a postulated lag time of 15 ± 1 days.
Table 3. Associations between follicle-stimulating hormone 
(FSH) or pregnanediol glucuronide (PdG) and urinary 
melatonin sulfate (aMT6) levels across a range of lag times 





Lag between each 
candidate predictor 
and aMT6, db
Association of each 
candidate predictor with 
aMT6 level, ng/mL
β coefficient P R2
FSH, mIU/mL 11 0.005 .83 0.524
 12 –0.003 .89 0.520
 13 –0.011 .63 0.519
 14 0.037 .10 0.523
 15 –0.007 .76 0.524
 16 0.002 .91 0.523
PdG, μg/mL 4 0.338 .42 0.522
 5 0.687 .10 0.525
 6 1.116 .01 0.526
 7 1.122 .01 0.522
 8 1.120 .01 0.529
 9 1.274 .00 0.526
 10 1.299 .00 0.529
 11 1.461 .001 0.530
 12 1.437 .001 0.525
 13 1.168 .00 0.523
 14 0.645 .12 0.523
aBased on associations observed in the evidence of luteal activity (ELA) 
cycles (Table  2), we pursued additional analysis of the relations between 
aMT6s and FSH and PdG, using data both from ELA and no evidence of 
luteal activity cycles.
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regression analyses disclosed an association between 
progesterone and melatonin, the magnitude of that as-
sociation was stronger when we modeled progesterone 
predicting melatonin, rather than the reverse. The direc-
tion of the stronger association is at odds with the idea 
that melatonin stabilizes the CL. However, melatonin 
levels in preovulatory follicular fluid are approximately 
3-fold higher than are serum levels [26]. It is possible 
that the level of intrafollicular melatonin (not cap-
tured by the present study) is what supports the subse-
quent production of progesterone and stabilizes the CL. 
Another distinct function of melatonin may be to govern 
the menstrual cycle through its reciprocal relation with 
gonadotropin-releasing hormone pulse frequency [27]. 
The gonadotropin-releasing hormone pulse generator is 
slowest (approximately every 4-6 hours) in the late luteal 
phase, when melatonin is high, and is fastest (approxi-
mately circhoral) at midcycle, when melatonin is low 
[28]. Therefore, the late-luteal melatonin increase origin-
ally described by Wetterberg and confirmed here may be 
part of the coordinated pacemaker system that regulates 
the human menstrual cycle [24].
Longitudinal analysis revealed that the whole cycle ex-
cretion of aMT6s was 30% lower when participants were 
postmenopausal compared to when they were premeno-
pausal. However, because of collinearity between age and 
menopause stage in this small study, we are unable to sep-
arate their effects. It is plausible that chronological aging 
and reproductive aging (menopause) have independent 
influences on melatonin levels across the lifespan. Besides 
its preeminent function as a circadian pacemaker, some 
have hypothesized that melatonin is etiologic in the de-
velopment of age-related diseases [7]. However, support 
for this concept comes mainly from cross-sectional studies 
that report lower melatonin secretion with increasing age, 
corresponding to the rise of potentially melatonin-related 
conditions. Similarly, the overlap between MT symp-
toms and those that may be influenced by melatonin (eg, 
poor sleep quality, dysphoric mood) raises the question 
of whether melatonin declines in relation to menopause 
and whether such a decline underlies some menopause-
associated conditions [10, 11, 29-31]. One cross-sectional 
study of 17 cycling women and 18 postmenopausal 
women found substantially lower melatonin levels in 
postmenopause (but was unable to adjust for age because 
of collinearity with menopause) [32]. To our knowledge, 
no longitudinal studies have had measures of both mela-
tonin and outcomes of interest in relation to aging or 
menopause.
The principal limitations of this study are its small size, 
a design that created confounding between MT stage and 
age, and potential misestimation of absolute aMT6s levels 
due to long-term storage. This confounding resulted from 
our selection of premenopausal and postmenopausal ob-
servations that maximized the amount of chronologic time 
between ELA and NELA collections. Therefore, there was 
complete separation of chronological age between the 
premenopausal and postmenopausal collections. Thus, 
although the study was able to describe patterns of hor-
mones and their interrelations during the menstrual cycle, 
it was unable to discern whether menopause and aging in-
dependently influenced the observed, longitudinal drop in 
melatonin excretion. The long-term stability of aMT6s is 
robust [33], but urine samples may have concentrated in 
the freezers, which could result in falsely inflated absolute 
levels of aMT6s. However, it is likely that all repository 
samples would be affected similarly by such concentra-
tion. Therefore, the patterns of aMT6s within each col-
lection and the differences between premenopausal and 
postmenopausal levels should not be affected. Study 
strengths include daily sampling and an integrated, over-
night assessment of melatonin, gonadotropin, and sex-
steroid hormone excretion. Moreover, although the sample 
size is modest, it is substantially greater than those of prior 
reports and the first sample in which aMT6s was assessed 
longitudinally in premenopause and postmenopause.
In summary, this study contributes to our understanding 
of the biology of the human menstrual cycle by confirming 
a late-luteal melatonin peak that follows the progesterone 
rise. This melatonin increase appears to be signaled by pro-
gesterone; thus, circulating levels of late-luteal melatonin 
are more likely to be involved in cycle pacemaker control 
rather than influencing progesterone production. Finally, a 
definitive, 30% diminution of melatonin occurred in the 
postmenopausal collections, but whether this is an aging 
and/or menopause effect cannot be determined within the 
present design. Larger, longitudinal studies of melatonin in 
relation to aging and menopause are warranted.
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